Ser462
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser462  -  SMAD1 (human)

Site Information
GsPHNPIssVs____   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448361

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 8 , 9 ) , mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 ) , mutation of modification site ( 8 , 9 ) , phosphoamino acid analysis ( 9 ) , phosphopeptide mapping ( 9 )
Disease tissue studied:
cervical cancer ( 7 ) , cervical adenocarcinoma ( 7 ) , gastric cancer ( 5 ) , gastric carcinoma ( 5 ) , lung cancer ( 3 , 4 , 6 ) , non-small cell lung cancer ( 3 , 4 , 6 ) , non-small cell lung adenocarcinoma ( 3 , 4 , 6 ) , non-small cell squamous cell lung carcinoma ( 3 , 4 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
BMPR1B (human) ( 8 , 9 )
Kinases, in vitro:
BMPR1B (human) ( 8 , 9 )
Treatments:
EGF ( 8 ) , HGF ( 8 ) , serum_starvation ( 8 ) , wortmannin ( 8 )

Downstream Regulation
Effects of modification on SMAD1:
activity, induced ( 9 ) , intracellular localization ( 8 , 9 ) , molecular association, regulation ( 9 )
Effects of modification on biological processes:
transcription, altered ( 9 )
Induce interaction with:
SMAD4 (human) ( 9 )

References 

1

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

2

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

3

Moritz A (2010) CST Curation Set: 10595; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Su11274; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

4

Moritz A (2010) CST Curation Set: 10596; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

5

Moritz A (2010) CST Curation Set: 10020; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

6

Moritz A (2010) CST Curation Set: 9980; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

7

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

8

Kretzschmar M, Doody J, Massagué J (1997) Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature 389, 618-22
9335504   Curated Info

9

Kretzschmar M, et al. (1997) The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. Genes Dev 11, 984-95
9136927   Curated Info